Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $28.55

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $28.5455.

A number of equities research analysts have recently issued reports on the stock. Citigroup lifted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. TD Cowen lifted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Finally, Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its holdings in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Root Financial Partners LLC increased its stake in shares of Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $41,000. Torren Management LLC acquired a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $46,000. Finally, Bessemer Group Inc. increased its position in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $25.95 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a fifty-two week low of $13.39 and a fifty-two week high of $27.72. The stock has a market cap of $12.96 billion, a PE ratio of -51.90, a price-to-earnings-growth ratio of 1.67 and a beta of 1.68. The firm’s fifty day simple moving average is $23.58 and its 200-day simple moving average is $23.87.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts expect that Elanco Animal Health will post 1.11 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.